Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow INTENSITY THERAPEUTICS, INC.

Get SEC filing alerts via email and in your feed for INTENSITY THERAPEUTICS, INC.

INTS

INTENSITY THERAPEUTICS, INC.

About INTENSITY THERAPEUTICS, INC.

Intensity Therapeutics Inc. is a biotechnology company focused on developing localized cancer treatments that activate the immune system. Its lead product, INT230-6, combines proven chemotherapies with a proprietary delivery platform to enhance tumor dispersion, kill cancer cells, and stimulate systemic immune responses. The company targets solid tumors, including breast cancer and sarcoma, aiming to improve efficacy, reduce toxicity, and transform cancer therapy through intratumoral injections and immune activation.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from INTENSITY THERAPEUTICS, INC.

1
1
INTENSITY THERAPEUTICS, INC. Intensity Therapeutics Reports $2.4 Million Net Loss in Q1 2026, Plans for Future Funding

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
INTENSITY THERAPEUTICS, INC. Intensity Therapeutics Reports $11.6 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
INTENSITY THERAPEUTICS, INC. Intensity Therapeutics Reports Q3 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
INTENSITY THERAPEUTICS, INC. Intensity Therapeutics Reports Improved Financial Results for Q2 2025 with Reduced Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
INTENSITY THERAPEUTICS, INC. Intensity Therapeutics Reports $3.3 Million Net Loss in Q1 2025, Highlights Funding Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
INTENSITY THERAPEUTICS, INC. Intensity Therapeutics Reports Increased Net Loss and Launches Phase 3 Trials for INT230-6

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
INTENSITY THERAPEUTICS, INC. Intensity Therapeutics Reports Significant Financial Challenges, Net Loss, and Doubt About Its Ability to Continue as a Going Concern

Via official filing (AI summary) | over 1 year ago | 0 comments